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Response to letter to editor regarding Immunoglobulin G4-related disease in a dog
Dear Dr DiBartola and Dr Hinchcliff
Thank you for the opportunity to address the points made by Drs.
Watson et al on our recent case of immunoglobulin G4-related disease (IgG4-RD) in a dog. We agree that development of diagnostic criteria of IgG4-RD in dogs deserves attention, should be based on evaluation of a broad case set, and should involve a consensus opinion from multiple clinicians and researchers, as was done in human medicine. 1 We look forward to being part of that conversation.
The consensus comprehensive diagnostic criteria for IgG4-RD in humans involve a combination of (1) characteristic diffuse/localized swelling or masses in single or multiple organs; (2) Mikulicz disease is defined as swelling of 2 pairs of the lacrimal, parotid, or submandibular glands and the head and neck-limited disease is expected to have mass-like lesions; these 2 phenotypes were present in 46% of 765 human patients. 3 The parotid and salivary gland enlargement in our case is consistent with IgG4-RD in humans. The IgG4-RD cytology affected human cases also had a variable but occasionally marked eosinophilia, lower numbers of neutrophils and macrophages, and a lymphocyte predominance, similar to what we describe in our case of IgG4-RD in a dog. 5 The cytologic features in our IgG4-RD are consistent with cytologic findings in humans with IgG4-RD. 4 . Multiple studies confirm that the incidence of peripheral eosinophilia in all humans with IgG4-RD, including both atopic and nonatopic cases, is~40%. 6 The eosinophilia of IgG4-RD in humans is commonly of the same magnitude as was observed in our dog with IgG4-RD case and responds well to steroids, similar to our IgG4-RD case. 6 Description of atopy is not needed to explain peripheral eosinophilia and lack of findings of atopy does not rule out IgG4-RD in our case.
Descriptions of humans with

5.
Immunoglobulin G4-related disease in humans has been misdiagnosed as hypereosinophilia syndrome but the two diseases are not mutually exclusive; concurrent hypereosinophilia syndrome and IgG4-RD have been reported in humans. 6 Bone marrow evaluation in our dog with IgG4-RD case was inconsistent with a myeloid clonal process and a T-cell clone was not found by polymerase chain reaction (PCR) for antigen receptor rearrangements (PARR) to support a paraneoplastic cause of the hypereosinophlia. 6 Additionally, lesion distribution in our case was inconsistent with hypereosinophilia syndrome in dogs, in our experience. We do not know the relationship of IgG4-RD in dogs and cases previously diagnosed as hypereosinophilia syndrome but suspect that at least some cases of canine IgG4-RD have been diagnosed as idiopathic hypereosinophilia syndrome in the past.
Serum IgG4 concentration is significantly higher in humans with
IgG4-RD than in other diseases with increased serum IgG4 concentrations, including cancer (excluding IgG4-producing myeloma), autoimmune disorders, vasculitis, infections, and other causes such as hypereosinophilia syndrome. 7 Our lab has documented IgG4 by immunofixation in cases with a history of parasitic infections, inflammation, cancer, and atopy/allergy, among other causes.
Except for the two cases of IgG4-producing multiple myeloma published as part of our evaluation of the immunofixation protocol, 8 It is not surprising that differences are present between our dog with IgG4-RD and English Cocker Spaniels with chronic pancreatitis.
Both phenotyping studies of IgG4-RD in humans segregated the pancreatic predominant disease phenotype from other phenotypes and documented distinct differences of signalment, risk factors, clinical findings, and clinical progression between phenotypes. 3, 4 The observations provided by Dr Watson et al are very useful as they suggest that a similar breadth of presentations may be found in dogs with IgG4-RD. We expect that their in-review manuscript lays out data from English Cocker Spaniels with chronic pancreatitis fully and provides useful information on the pancreatic predominant phenotype of IgG4-RD in the dog. Rigorous comparison of our dog with IgG4-RD with chronic pancreatitis cases in dogs with IgG4-RD should be delayed until a full evaluation of that data can be made.
We find IgG4-RD in humans a fascinating disease and are intrigued by the potential that it shares as diverse a presentation in dogs as it does in humans. We expect that as awareness of this disease process increases, more cases will be described and further clarification of the diagnostic criteria for IgG4-RD in dogs will be possible. 
